Rolapitant, Tesaro’s experimental therapy for preventing some nasty side effects of chemo, has hit all the primary and secondary goals, helping boost the company’s stock today and leaving it on track to deliver an NDA to the FDA in the next few months.

…read more

Source: Tesaro preps for a Merck showdown after seeing positive PhIII results for rolapitant


0 No comments